|
Sep 16
|
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
|
|
Jul 25
|
Investing in Alimera Sciences (NASDAQ:ALIM) a year ago would have delivered you a 68% gain
|
|
Jun 27
|
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
|
|
Jun 25
|
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
|
|
Jun 24
|
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal
|
|
Jun 24
|
Alimera Sciences shares jump by 77% after being acquired by ANI
|
|
Jun 24
|
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
|
|
May 15
|
Alimera Sciences Inc (ALIM) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ...
|
|
May 14
|
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 14
|
Alimera Sciences Reports First Quarter 2024 Results
|
|
May 7
|
Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences
|
|
Apr 30
|
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
|
|
Mar 20
|
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 19
|
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
|
|
Mar 8
|
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript
|
|
Mar 8
|
Q4 2023 Alimera Sciences Inc Earnings Call
|
|
Mar 7
|
Alimera Sciences Inc (ALIM) Reports Significant Revenue Growth in Q4 and Full Year 2023
|
|
Mar 7
|
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 7
|
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
|
|
Mar 6
|
Alimera Sciences, Inc. (NASDAQ:ALIM) Has Found A Path To Profitability
|